Switch to:
Also traded in: Germany, Japan, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.76
OTCPK:TKPYY's Cash-to-Debt is ranked lower than
68% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. OTCPK:TKPYY: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:TKPYY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.7  Med: 0.99 Max: N/A
Current: 0.76
Equity-to-Asset 0.48
OTCPK:TKPYY's Equity-to-Asset is ranked lower than
72% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OTCPK:TKPYY: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:TKPYY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.55 Max: 0.76
Current: 0.48
0.47
0.76
Interest Coverage 9.84
OTCPK:TKPYY's Interest Coverage is ranked lower than
74% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. OTCPK:TKPYY: 9.84 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TKPYY' s Interest Coverage Range Over the Past 10 Years
Min: 3.18  Med: 189.06 Max: 1856.28
Current: 9.84
3.18
1856.28
Piotroski F-Score: 5
Altman Z-Score: 2.45
Beneish M-Score: -2.39
WACC vs ROIC
3.73%
7.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 10.45
OTCPK:TKPYY's Operating Margin % is ranked higher than
57% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. OTCPK:TKPYY: 10.45 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:TKPYY' s Operating Margin % Range Over the Past 10 Years
Min: -7.27  Med: 18.74 Max: 35.13
Current: 10.45
-7.27
35.13
Net Margin % 7.64
OTCPK:TKPYY's Net Margin % is ranked higher than
55% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. OTCPK:TKPYY: 7.64 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:TKPYY' s Net Margin % Range Over the Past 10 Years
Min: -8.2  Med: 12.39 Max: 25.85
Current: 7.64
-8.2
25.85
ROE % 6.84
OTCPK:TKPYY's ROE % is ranked higher than
50% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. OTCPK:TKPYY: 6.84 )
Ranked among companies with meaningful ROE % only.
OTCPK:TKPYY' s ROE % Range Over the Past 10 Years
Min: -6.33  Med: 8.85 Max: 15.12
Current: 6.84
-6.33
15.12
ROA % 3.34
OTCPK:TKPYY's ROA % is ranked lower than
51% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. OTCPK:TKPYY: 3.34 )
Ranked among companies with meaningful ROA % only.
OTCPK:TKPYY' s ROA % Range Over the Past 10 Years
Min: -3.29  Med: 6.12 Max: 12
Current: 3.34
-3.29
12
ROC (Joel Greenblatt) % 29.08
OTCPK:TKPYY's ROC (Joel Greenblatt) % is ranked higher than
72% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. OTCPK:TKPYY: 29.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:TKPYY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -19.36  Med: 48.9 Max: 207.72
Current: 29.08
-19.36
207.72
3-Year Revenue Growth Rate 5.20
OTCPK:TKPYY's 3-Year Revenue Growth Rate is ranked lower than
53% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. OTCPK:TKPYY: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:TKPYY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.2  Med: 5.05 Max: 11.6
Current: 5.2
0.2
11.6
3-Year EBITDA Growth Rate -4.40
OTCPK:TKPYY's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. OTCPK:TKPYY: -4.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:TKPYY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: -1.15 Max: 24.8
Current: -4.4
-28.3
24.8
3-Year EPS without NRI Growth Rate -18.50
OTCPK:TKPYY's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. OTCPK:TKPYY: -18.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:TKPYY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.5  Med: -0.8 Max: 31.4
Current: -18.5
-24.5
31.4
GuruFocus has detected 6 Warning Signs with Takeda Pharmaceutical Co Ltd $OTCPK:TKPYY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:TKPYY's 10-Y Financials

Financials (Next Earnings Date: 2017-05-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:ESALF, OTCPK:SGIOY, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:APNHF, NYSE:PRGO, OTCPK:HLUYY, OTCPK:SFOSF, OTCPK:IPSEY, OTCPK:ORINY, OTCPK:TAISF, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:TARO, NYSE:MNK, NAS:OPK » details
Traded in other countries:TKD.Germany, 4502.Japan, 0RN3.UK,
Headquarter Location:Japan
Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Takeda is Japan's largest pharmaceutical company, with annual revenue around $15 billion and a focus on four therapeutic areas: oncology, gastroenterology, cardiovascular/metabolic, and neurology. Roughly 40% of its revenue comes from Japan. The Millennium acquisition (2008) brought rights to Velcade, Ninlaro, and Entyvio. The Nycomed acquisition (2011) expanded Takeda's exposure to Europe and emerging markets. Other notable products include candesartan (blood pressure), leuprorelin (prostate cancer), and lansoprazole/pantoprazole (GERD).

Ratios

vs
industry
vs
history
PE Ratio 30.94
TKPYY's PE Ratio is ranked lower than
55% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. TKPYY: 30.94 )
Ranked among companies with meaningful PE Ratio only.
TKPYY' s PE Ratio Range Over the Past 10 Years
Min: 6.78  Med: 21.61 Max: 90.66
Current: 30.94
6.78
90.66
Forward PE Ratio 24.88
TKPYY's Forward PE Ratio is ranked lower than
86% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. TKPYY: 24.88 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.94
TKPYY's PE Ratio without NRI is ranked lower than
56% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. TKPYY: 30.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
TKPYY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.78  Med: 21.61 Max: 90.66
Current: 30.94
6.78
90.66
Price-to-Owner-Earnings 20.08
TKPYY's Price-to-Owner-Earnings is ranked higher than
70% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. TKPYY: 20.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TKPYY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.64  Med: 26.45 Max: 581.37
Current: 20.08
11.64
581.37
PB Ratio 2.07
TKPYY's PB Ratio is ranked higher than
65% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. TKPYY: 2.07 )
Ranked among companies with meaningful PB Ratio only.
TKPYY' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.56 Max: 2.44
Current: 2.07
1.22
2.44
PS Ratio 2.36
TKPYY's PS Ratio is ranked higher than
58% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TKPYY: 2.36 )
Ranked among companies with meaningful PS Ratio only.
TKPYY' s PS Ratio Range Over the Past 10 Years
Min: 1.67  Med: 2.2 Max: 12.29
Current: 2.36
1.67
12.29
EV-to-EBIT 22.68
TKPYY's EV-to-EBIT is ranked lower than
55% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. TKPYY: 22.68 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 11.5 Max: 46.2
Current: 22.68
-47.1
46.2
EV-to-EBITDA 12.13
TKPYY's EV-to-EBITDA is ranked higher than
71% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. TKPYY: 12.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -438  Med: 10.6 Max: 237.7
Current: 12.13
-438
237.7
Shiller PE Ratio 12.15
TKPYY's Shiller PE Ratio is ranked higher than
94% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. TKPYY: 12.15 )
Ranked among companies with meaningful Shiller PE Ratio only.
TKPYY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.73  Med: 10.59 Max: 12.48
Current: 12.15
8.73
12.48
Current Ratio 1.73
TKPYY's Current Ratio is ranked lower than
67% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. TKPYY: 1.73 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.09 Max: 4
Current: 1.73
1.21
4
Quick Ratio 1.50
TKPYY's Quick Ratio is ranked lower than
62% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. TKPYY: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.73 Max: 3.64
Current: 1.5
1
3.64
Days Inventory 160.56
TKPYY's Days Inventory is ranked lower than
71% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. TKPYY: 160.56 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 132.84  Med: 162.63 Max: 180.99
Current: 160.56
132.84
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.46
TKPYY's Dividend Yield % is ranked higher than
87% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. TKPYY: 3.46 )
Ranked among companies with meaningful Dividend Yield % only.
TKPYY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.71  Med: 4.35 Max: 6.48
Current: 3.46
2.71
6.48
Dividend Payout Ratio 1.05
TKPYY's Dividend Payout Ratio is ranked lower than
91% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. TKPYY: 1.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TKPYY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.62 Max: 1.77
Current: 1.05
0.33
1.77
Forward Dividend Yield % 3.28
TKPYY's Forward Dividend Yield % is ranked higher than
83% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. TKPYY: 3.28 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.46
TKPYY's 5-Year Yield-on-Cost % is ranked higher than
72% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. TKPYY: 3.46 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TKPYY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.71  Med: 4.35 Max: 6.48
Current: 3.46
2.71
6.48
3-Year Average Share Buyback Ratio 0.30
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. TKPYY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0 Max: 3.9
Current: 0.3
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 7.85
TKPYY's Price-to-Tangible-Book is ranked lower than
76% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. TKPYY: 7.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TKPYY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.85  Med: 7.02 Max: 13.07
Current: 7.85
1.85
13.07
Price-to-Intrinsic-Value-Projected-FCF 2.06
TKPYY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
57% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. TKPYY: 2.06 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TKPYY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.17  Med: 1.44 Max: 2.11
Current: 2.06
1.17
2.11
Price-to-Median-PS-Value 1.08
TKPYY's Price-to-Median-PS-Value is ranked higher than
55% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. TKPYY: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TKPYY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1 Max: 5.17
Current: 1.08
0.81
5.17
Price-to-Graham-Number 3.29
TKPYY's Price-to-Graham-Number is ranked lower than
69% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. TKPYY: 3.29 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TKPYY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.69  Med: 2.67 Max: 4.79
Current: 3.29
0.69
4.79
Earnings Yield (Greenblatt) % 4.39
TKPYY's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. TKPYY: 4.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TKPYY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 6.7 Max: 23.8
Current: 4.39
2.2
23.8
Forward Rate of Return (Yacktman) % -27.20
TKPYY's Forward Rate of Return (Yacktman) % is ranked lower than
95% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. TKPYY: -27.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TKPYY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -46.9  Med: -16.6 Max: 15.8
Current: -27.2
-46.9
15.8

More Statistics

Revenue (TTM) (Mil) $15,891
EPS (TTM) $ 0.80
Beta0.34
Short Percentage of Float0.00%
52-Week Range $19.96 - 25.05
Shares Outstanding (Mil)1,567.34

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 15,366 16,259
EPS ($) 0.73 0.95
EPS without NRI ($) 0.73 0.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.82%
Dividends per Share ($) 0.80 0.80
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to Advanc Apr 27 2017 
Teva Is a Hold Nov 30 2016 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to... Apr 27 2017
Raleigh's PRA Health Sciences clocks double-digit growth in first quarter Apr 26 2017
[$$] Demands of disease drive vaccine science Apr 18 2017
Takeda Pharmaceutical Company Limited -- Moody's: Japan economic momentum building, on the back of... Apr 17 2017
Takeda's largest study brings dengue vaccine step closer Apr 05 2017
4 FDA Decisions to Watch Out for in Apr 2017 Apr 03 2017
Takeda Receives Award for Supporting Employees Who Serve In Military Mar 17 2017
Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue? Mar 14 2017
PRA Health Sciences, Inc. -- Moody's upgrades PRA Holdings' CFR to Ba3; outlook positive Feb 28 2017
Takeda Pharmaceutical Company Limited -- Moody's confirms Takeda Pharmaceutical's A1 ratings;... Feb 27 2017
Takeda and Cognition Kit partner in study to pilot wearable software in patients with Major... Feb 23 2017
Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and... Feb 17 2017
Raleigh's PRA Health Sciences gains 60 employees after Takeda deal Feb 16 2017
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss Feb 10 2017
Why Ariad Pharmaceuticals Stock Nearly Doubled in January Feb 06 2017
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 2,... Feb 02 2017
Japan's Takeda committed to single-digit U.S. drug price rises Feb 01 2017
Exelixis Inks Partnership with Takeda for Cabometyx in Japan Jan 31 2017
Ariad played hardball to boost Takeda buyout price, federal filings show Jan 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)